The total number of records retrieved from this search are 9. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_5025	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result68% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5026	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result36% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5027	Virus nameVaccinia virus	Virus strainVG9	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result26% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5028	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result68% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5029	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5030	Virus nameVaccinia virus	Virus strainVG9-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5031	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result65% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5032	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result36% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492
IDOV_5033	Virus nameVaccinia virus	Virus strainWR-EGFP	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationAddition of EGFP gene in tk locus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman gastric carcinoma cell line	Cell lineSCG-7901	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result22% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28465492